Business Context and Reporting Period
Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1995
Business Overview: UTMD manufactures medical devices in three primary categories: critical care (invasive blood pressure monitoring), obstetrics (intrauterine pressure monitoring), and gynecology (electrosurgery systems). The company holds significant market share in its core products and relies heavily on OEM relationships, particularly with Baxter Healthcare Corporation.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Net Sales | $9,754,041 | $9,357,530 |
| Gross Margin | $4,371,363 (44.8%) | $4,173,043 (44.6%) |
| Income from Operations | $2,531,148 (25.9%) | $2,390,575 (25.5%) |
| Net Income | $1,820,517 | $1,653,346 |
| Earnings Per Share (Diluted) | $0.18 | $0.15 |
| Cash Provided by Operating Activities | $3,266,192 | $2,237,251 |
| Cash and Investments (End of Period) | $9,335,927 | N/A |
| Total Liabilities | $4,102,366 | N/A |
Note: Q1 1994 cash and investment balances are not explicitly aggregated in the text, though Q1 1995 cash was $4,187,291 and investments were $5,148,636.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.2% year-over-year, driven by growth in critical care (+4%) and obstetrics (+7%) segments, partially offset by a 6% decline in gynecology sales.
- Profitability: Net income rose 10.1% to $1.82 million, outpacing revenue growth due to improved gross margins and higher non-operating income.
- Expense Management: Operating expenses as a percentage of sales decreased to 18.8% from 19.0%. While R&D expenses increased 26% (to 4.2% of sales), SG&A expenses declined to 14.6% of sales.
- Liquidity: Cash and investments increased by $2.2 million from the prior quarter end, despite $881,000 spent on share repurchases. Operating cash flow improved significantly due to a $981,000 reduction in accounts receivable.
- Share Count: Weighted average shares outstanding decreased to 10.07 million from 10.97 million in the prior year, boosting EPS by 20.0%.
Guidance, Outlook, and Risks
- Capital Expenditures: The company announced a $4 million commitment to build a manufacturing facility in Athlone, Ireland, funded by current cash, with production expected in early 1996.
- Product Launches: Management anticipates increased operating expenses in the second half of 1995 due to the launch of new products (Cordguard, Liberty, and Lumin) and the addition of direct sales representatives.
- Strategic Agreements: New distribution agreements with Baxter Healthcare Corporation were signed in January 1995 to increase order predictability and lower administrative costs.
- Share Repurchases: The company continues its share repurchase program to offset dilution from employee stock options. Approximately $17.6 million has been spent since November 1992.
- Risks: Results for a single quarter may not be indicative of full-year performance. The company relies heavily on international sales for critical care products and specific OEM relationships.
Investor Verification Checklist
- Verify the timeline and funding status of the $4 million Ireland manufacturing facility.
- Monitor the impact of new product launches (Cordguard, Liberty, Lumin) on operating expense ratios in H2 1995.
- Confirm the sustainability of the 26% increase in R&D spending and its correlation with the three FDA 510(k) concurrences received in early 1995.
- Assess the stability of the 66% revenue concentration from the Baxter Healthcare OEM relationship within the critical care segment.
- Review the continued effectiveness of the share repurchase program in maintaining EPS growth targets.